Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2008

01-09-2008 | Epidemiology

Association of polymorphisms of angiogenesis genes with breast cancer

Authors: Bryan P. Schneider, Milan Radovich, George W. Sledge, Jason D. Robarge, Lang Li, Anna M. Storniolo, Suzanne Lemler, Anne T. Nguyen, Bradley A. Hancock, Michael Stout, Todd Skaar, David A. Flockhart

Published in: Breast Cancer Research and Treatment | Issue 1/2008

Login to get access

Abstract

Background

Few studies have systematically explored a pathway approach: to test the association of multiple polymorphisms from multiple genes important to angiogenesis simultaneously with risk of breast cancer. We report our preliminary data evaluating the association of polymorphisms from seven genes known to influence angiogenesis with the likelihood of having breast cancer.

Methods

We recruited 715 controls and 520 subjects with breast cancer. Subjects provided a blood specimen and completed a questionnaire that included common breast cancer risk factors and breast cancer status. We evaluated candidate polymorphisms in the following genes: Hypoxia Inducible Factor-1 alpha (HIF1α), Vascular Endothelial Growth Factor (VEGF), VEGF Receptor 1 (VEGFR-1), VEGFR-2, endothelial Nitric Oxide Synthase (eNOS), Neuropilin-1 (NRP-1) and Neuropilin-2 (NRP-2). Testing for associations between each polymorphism and the presence or absence of breast cancer was performed.

Results

VEGF-2578 AA and -1498 CC genotypes were more common in cancer cases than controls (P = 0.06 and P = 0.04, respectively). These two genotypes remained significant predictors of breast cancer status after adjusting for non-genetic risk factors estimated by the Gail model (P = 0.03 and P = 0.03, respectively). When comparing women with invasive versus pre-invasive breast cancer, the eNOS-786 TT and eNOS 894 GG genotypes were associated with a greater likelihood of invasive disease and the eNOS 894 GG genotype was associated with a greater likelihood of having metastatic disease.

Conclusion

There is an association of the VEGF-2578A and -1498C alleles with increased breast cancer risk. This association remains significant when adjusted for Gail score-related risk factors.
Appendix
Available only for authorised users
Literature
3.
4.
go back to reference Plate KH, Breier G, Risau W (1994) Molecular mechanisms of developmental and tumor angiogenesis. Brain Pathol 4:207–218PubMedCrossRef Plate KH, Breier G, Risau W (1994) Molecular mechanisms of developmental and tumor angiogenesis. Brain Pathol 4:207–218PubMedCrossRef
5.
go back to reference Weinstat-Saslow D, Steeg PS (1994) Angiogenesis and colonization in the tumor metastatic process: basic and applied advances. FASEB J 8:401–407PubMed Weinstat-Saslow D, Steeg PS (1994) Angiogenesis and colonization in the tumor metastatic process: basic and applied advances. FASEB J 8:401–407PubMed
6.
go back to reference Parangi S, O’Reilly M, Christofori G et al (1996) Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci U S A 93:2002–2007PubMedCrossRef Parangi S, O’Reilly M, Christofori G et al (1996) Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci U S A 93:2002–2007PubMedCrossRef
8.
go back to reference Schneider BP, Sledge GW Jr (2007) Drug insight: VEGF as a therapeutic target for breast cancer. Nat Clin Pract Oncol 4:181–189PubMedCrossRef Schneider BP, Sledge GW Jr (2007) Drug insight: VEGF as a therapeutic target for breast cancer. Nat Clin Pract Oncol 4:181–189PubMedCrossRef
9.
go back to reference Guinebretiere JM, Le Monique G, Gavoille A et al (1994) Angiogenesis and risk of breast cancer in women with fibrocystic disease. J Natl Cancer Inst 86:635–636PubMedCrossRef Guinebretiere JM, Le Monique G, Gavoille A et al (1994) Angiogenesis and risk of breast cancer in women with fibrocystic disease. J Natl Cancer Inst 86:635–636PubMedCrossRef
10.
go back to reference Guidi AJ, Fischer L, Harris JR et al (1994) Microvessel density and distribution in ductal carcinoma in situ of the breast. J Natl Cancer Inst 86:614–619PubMedCrossRef Guidi AJ, Fischer L, Harris JR et al (1994) Microvessel density and distribution in ductal carcinoma in situ of the breast. J Natl Cancer Inst 86:614–619PubMedCrossRef
11.
go back to reference Guidi AJ, Schnitt SJ, Fischer L et al (1997) Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer 80:1945–1953PubMedCrossRef Guidi AJ, Schnitt SJ, Fischer L et al (1997) Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer 80:1945–1953PubMedCrossRef
12.
go back to reference Weidner N, Semple JP, Welch WR et al (1991) Tumor angiogenesis and metastasis–correlation in invasive breast carcinoma. N Engl J Med 324:1–8PubMedCrossRef Weidner N, Semple JP, Welch WR et al (1991) Tumor angiogenesis and metastasis–correlation in invasive breast carcinoma. N Engl J Med 324:1–8PubMedCrossRef
13.
go back to reference Weidner N, Folkman J, Pozza F et al (1992) Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:1875–1887PubMedCrossRef Weidner N, Folkman J, Pozza F et al (1992) Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:1875–1887PubMedCrossRef
14.
go back to reference Schneider BP, Skaar TC, Sledge GW et al (2006) Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes. Breast Cancer Res Treat 96:209–215PubMedCrossRef Schneider BP, Skaar TC, Sledge GW et al (2006) Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes. Breast Cancer Res Treat 96:209–215PubMedCrossRef
15.
go back to reference Lin CC, Wu HC, Tsai FJ et al (2003) Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for prostate cancer. Urology 62:374–377PubMedCrossRef Lin CC, Wu HC, Tsai FJ et al (2003) Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for prostate cancer. Urology 62:374–377PubMedCrossRef
16.
go back to reference McCarron SL, Edwards S, Evans PR et al (2002) Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 62:3369–3372PubMed McCarron SL, Edwards S, Evans PR et al (2002) Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 62:3369–3372PubMed
17.
go back to reference Krippl P, Langsenlehner U, Renner W et al (2003) A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 106:468–471PubMedCrossRef Krippl P, Langsenlehner U, Renner W et al (2003) A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 106:468–471PubMedCrossRef
18.
go back to reference Cheon KT, Choi KH, Lee HB et al (2000) Gene polymorphisms of endothelial nitric oxide synthase and angiotensin-converting enzyme in patients with lung cancer. Lung 178:351–360PubMedCrossRef Cheon KT, Choi KH, Lee HB et al (2000) Gene polymorphisms of endothelial nitric oxide synthase and angiotensin-converting enzyme in patients with lung cancer. Lung 178:351–360PubMedCrossRef
19.
go back to reference Medeiros R, Morais A, Vasconcelos A et al (2002) Endothelial nitric oxide synthase gene polymorphisms and genetic susceptibility to prostate cancer. Eur J Cancer Prev 11:343–350PubMedCrossRef Medeiros R, Morais A, Vasconcelos A et al (2002) Endothelial nitric oxide synthase gene polymorphisms and genetic susceptibility to prostate cancer. Eur J Cancer Prev 11:343–350PubMedCrossRef
20.
go back to reference Iughetti P, Suzuki O, Godoi PH et al (2001) A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma. Cancer Res 61:7375–7378PubMed Iughetti P, Suzuki O, Godoi PH et al (2001) A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma. Cancer Res 61:7375–7378PubMed
21.
go back to reference Howell WM, Bateman AC, Turner SJ et al (2002) Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma. Genes Immun 3:229–232PubMedCrossRef Howell WM, Bateman AC, Turner SJ et al (2002) Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma. Genes Immun 3:229–232PubMedCrossRef
22.
go back to reference Balasubramanian SP, Brown NJ, Reed MW (2002) Role of genetic polymorphisms in tumour angiogenesis. Br J Cancer 87:1057–1065PubMedCrossRef Balasubramanian SP, Brown NJ, Reed MW (2002) Role of genetic polymorphisms in tumour angiogenesis. Br J Cancer 87:1057–1065PubMedCrossRef
23.
go back to reference Ghilardi G, Biondi ML, Cecchini F et al (2003) Vascular invasion in human breast cancer is correlated to T→786C polymorphism of NOS3 gene. Nitric Oxide 9:118–122PubMedCrossRef Ghilardi G, Biondi ML, Cecchini F et al (2003) Vascular invasion in human breast cancer is correlated to T→786C polymorphism of NOS3 gene. Nitric Oxide 9:118–122PubMedCrossRef
24.
go back to reference Hefler LA, Ludwig E, Lampe D et al (2002) Polymorphisms of the endothelial nitric oxide synthase gene in ovarian cancer. Gynecol Oncol 86:134–137PubMedCrossRef Hefler LA, Ludwig E, Lampe D et al (2002) Polymorphisms of the endothelial nitric oxide synthase gene in ovarian cancer. Gynecol Oncol 86:134–137PubMedCrossRef
25.
go back to reference Medeiros RM, Morais A, Vasconcelos A et al (2002) Outcome in prostate cancer: association with endothelial nitric oxide synthase Glu-Asp298 polymorphism at exon 7. Clin Cancer Res 8:3433–3437PubMed Medeiros RM, Morais A, Vasconcelos A et al (2002) Outcome in prostate cancer: association with endothelial nitric oxide synthase Glu-Asp298 polymorphism at exon 7. Clin Cancer Res 8:3433–3437PubMed
26.
go back to reference Tanimoto K, Yoshiga K, Eguchi H et al (2003) Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis 24:1779–1783PubMedCrossRef Tanimoto K, Yoshiga K, Eguchi H et al (2003) Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis 24:1779–1783PubMedCrossRef
27.
go back to reference Jacobs EJ, Feigelson HS, Bain EB et al (2006) Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the cancer prevention study II cohort. Breast Cancer Res 8:R22PubMedCrossRef Jacobs EJ, Feigelson HS, Bain EB et al (2006) Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the cancer prevention study II cohort. Breast Cancer Res 8:R22PubMedCrossRef
28.
go back to reference Jin Q, Hemminki K, Enquist K et al (2005) Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res 11:3647–3653PubMedCrossRef Jin Q, Hemminki K, Enquist K et al (2005) Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res 11:3647–3653PubMedCrossRef
29.
go back to reference Langsenlehner U, Wolf G, Langsenlehner T et al (2007) Genetic polymorphisms in the vascular endothelial growth factor gene and breast cancer risk. The Austrian “tumor of breast tissue: incidence, genetics, and environmental risk factors” study. Breast Cancer Res Treat, doi:10.1007/s10549-007-9655-z Langsenlehner U, Wolf G, Langsenlehner T et al (2007) Genetic polymorphisms in the vascular endothelial growth factor gene and breast cancer risk. The Austrian “tumor of breast tissue: incidence, genetics, and environmental risk factors” study. Breast Cancer Res Treat, doi:10.​1007/​s10549-007-9655-z
30.
go back to reference Lu J, Wei Q, Bondy ML et al (2006) Promoter polymorphism (-786t>C) in the endothelial nitric oxide synthase gene is associated with risk of sporadic breast cancer in non-Hispanic white women age younger than 55 years. Cancer 107:2245–2253PubMedCrossRef Lu J, Wei Q, Bondy ML et al (2006) Promoter polymorphism (-786t>C) in the endothelial nitric oxide synthase gene is associated with risk of sporadic breast cancer in non-Hispanic white women age younger than 55 years. Cancer 107:2245–2253PubMedCrossRef
31.
go back to reference Choi JY, Lee KM, Noh DY et al (2006) Genetic polymorphisms of eNOS, hormone receptor status, and survival of breast cancer. Breast Cancer Res Treat 100:213–218PubMedCrossRef Choi JY, Lee KM, Noh DY et al (2006) Genetic polymorphisms of eNOS, hormone receptor status, and survival of breast cancer. Breast Cancer Res Treat 100:213–218PubMedCrossRef
32.
go back to reference Lemler S, Rufenbarger C, Skaar T et al (2005) Creating a DNA bank for pharmacogenomic epidemiology: the Friends for Life study. Breast Cancer Res Treat 94:S153 (Abstract #3084) Lemler S, Rufenbarger C, Skaar T et al (2005) Creating a DNA bank for pharmacogenomic epidemiology: the Friends for Life study. Breast Cancer Res Treat 94:S153 (Abstract #3084)
33.
go back to reference Costantino JP, Gail MH, Pee D et al (1999) Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 91:1541–1548PubMedCrossRef Costantino JP, Gail MH, Pee D et al (1999) Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 91:1541–1548PubMedCrossRef
34.
go back to reference Gail MH, Brinton LA, Byar DP et al (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879–1886PubMedCrossRef Gail MH, Brinton LA, Byar DP et al (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879–1886PubMedCrossRef
35.
go back to reference Barrett JC, Fry B, Maller J et al (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263–265PubMedCrossRef Barrett JC, Fry B, Maller J et al (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263–265PubMedCrossRef
36.
go back to reference Stevens A, Soden J, Brenchley PE et al (2003) Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 63:812–816PubMed Stevens A, Soden J, Brenchley PE et al (2003) Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 63:812–816PubMed
37.
go back to reference Cuzick J, Powles T, Veronesi U et al (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296–300PubMedCrossRef Cuzick J, Powles T, Veronesi U et al (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296–300PubMedCrossRef
Metadata
Title
Association of polymorphisms of angiogenesis genes with breast cancer
Authors
Bryan P. Schneider
Milan Radovich
George W. Sledge
Jason D. Robarge
Lang Li
Anna M. Storniolo
Suzanne Lemler
Anne T. Nguyen
Bradley A. Hancock
Michael Stout
Todd Skaar
David A. Flockhart
Publication date
01-09-2008
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9755-9

Other articles of this Issue 1/2008

Breast Cancer Research and Treatment 1/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine